Geoffrey Porges
Stock Analyst at SVB Leerink
(1.48)
# 3,540
Out of 5,127 analysts
113
Total ratings
46.67%
Success rate
-1.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $27.61 | +102.83% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $20.78 | +381.23% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $754.91 | +12.60% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $80.22 | -40.16% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $364.65 | -40.77% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $222.44 | -39.31% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $27.35 | -59.78% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $147.23 | -49.06% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $48.63 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $19.40 | -48.45% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $463.48 | -62.24% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $27.48 | +205.68% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $58.82 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $13.59 | +348.86% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $188.99 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $27.61
Upside: +102.83%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $20.78
Upside: +381.23%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $754.91
Upside: +12.60%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $80.22
Upside: -40.16%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $364.65
Upside: -40.77%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $222.44
Upside: -39.31%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $27.35
Upside: -59.78%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $147.23
Upside: -49.06%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $48.63
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $19.40
Upside: -48.45%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $463.48
Upside: -62.24%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $27.48
Upside: +205.68%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $58.82
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $13.59
Upside: +348.86%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $188.99
Upside: -